Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-07-13
- Target Recruit Count
- 2
- Registration Number
- NCT04064684
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Nebulized Budesonide Combined With Systemic Corticosteroid in Acute Severe Asthma
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- University of Monastir
- Target Recruit Count
- 60
- Registration Number
- NCT04016220
- Locations
- 🇹🇳
University of Monastir, Monastir, Tunisia
Efficacy Of Doxophylline As A Sparing Treatment For Inhaled Corticosteroids In Mexican Children With Asthma
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Universidad Autonoma de Nuevo Leon
- Target Recruit Count
- 60
- Registration Number
- NCT03879590
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Marinomed Biotech AG
- Target Recruit Count
- 82
- Registration Number
- NCT03755557
- Locations
- 🇦🇹
Vienna Challenge Chamber, Vienna, Austria
Therapeutic Approaches to Malnutrition Enteropathy
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 125
- Registration Number
- NCT03716115
- Locations
- 🇿🇼
Harare Central Hospital, Harare, Zimbabwe
🇿🇼Parirenyatwa Hospital, Harare, Zimbabwe
🇿🇲University Teaching Hospital, Nationalist Road, Lusaka, Zambia
Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis.
- Conditions
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 91
- Registration Number
- NCT03687515
Diesel Exhaust Induces Glucocorticoid Resistance
- Conditions
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT03615742
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
Study to Detect Oral Administration of Budesonide in Women.
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 4
- Registration Number
- NCT03537326
- Locations
- 🇪🇸
IMIM, Barcelona, Spain
Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
- Target Recruit Count
- 108
- Registration Number
- NCT03521063
- Locations
- 🇲🇽
Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico
Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates
- Conditions
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Kaiser Permanente
- Registration Number
- NCT03519061
- Locations
- 🇺🇸
Kaiser Permanante Orange County, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.